Insider · CIK 0001598602
D. Ryan Daws
Files at ENGN (enGene Therapeutics Inc.). First filing -, latest -.
In brief
D. Ryan Daws files SEC Form 4 as CFO at ENGN (enGene Therapeutics Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; D. Ryan Daws has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 30, 2026 | ENGN enGene Therapeutics Inc. | AGrant or award Stock Option (Right to Buy)derivative | +220,000 | $0.00 | $0 | 220,000 | Feb 3, 2026 |
| Jan 29, 2025 | ENGN enGene Therapeutics Inc. | AGrant or award Stock Option (Right to Buy)derivative | +280,000 | $0.00 | $0 | 280,000 | Jan 31, 2025 |
Questions about D. Ryan Daws
Answered from the filings on this page, as of the latest one.
Is D. Ryan Daws buying or selling?
D. Ryan Daws has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did D. Ryan Daws's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and D. Ryan Daws has 0.
Where does D. Ryan Daws file Form 4?
D. Ryan Daws has filed Form 4 at ENGN (enGene Therapeutics Inc.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.